Drugs / AZD2265
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07590934 | Jun 2026 → Sep 2029 expected | metastatic prostate carcinoma | AstraZeneca | Recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07611110 | May 2026 → Feb 2029 expected | prostate carcinoma | AstraZeneca | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AZD2265 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07590934 ↗ |
| Route | Intravenous | “administered as an intravenous (IV) injection” NCT07590934 ↗ |